


**Fig S1: Tumor regression from baseline as adjudicated by the independent review committee**

Responses were assessed in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The upper dotted line represents progression at 20% increase in size of target lesions, and the lower dotted line represents the RECIST 1.1 boundary for complete response or partial response at 30% decrease in size of target lesions. Patients with no postbaseline assessment (n=2) or no target lesions identified by the independent review committee before first dose (n=2) are not displayed in this figure.

\*Patients with an investigator-assessed best overall response of partial response.